Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 5/20 | 0.66 |
| ▸ | GABRD | O14764 | 5/20 | 0.66 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.66 |
| ▸ | GABRB1 | P18505 | 5/20 | 0.66 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.66 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.66 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.66 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.66 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.66 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.66 |
| ▸ | GABRA4 | P48169 | 5/20 | 0.66 |
| ▸ | GABRE | P78334 | 5/20 | 0.66 |
| ▸ | GABRA6 | Q16445 | 5/20 | 0.66 |
| ▸ | GABRG1 | Q8N1C3 | 5/20 | 0.66 |
| ▸ | GABRG3 | Q99928 | 5/20 | 0.66 |
| ▸ | GABRQ | Q9UN88 | 5/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2217085 | 0.91 | GABRP (0.80) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL28291469 | 0.89 | GABRP (0.82) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2043144 | 0.85 | GABRP (0.61) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2216825 | 0.85 | MAPT (0.77) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2360533 | 0.85 | GABRP (0.62) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL10624992 | 0.84 | GABRP (0.63) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL28291468 | 0.83 | GABRP (0.79) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL10857780 | 0.82 | STAT3 (0.69) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2361114 | 0.82 | GABRP (0.77) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL21731007 | 0.81 | KDM4E (0.59) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1634881-B1 | HARMINE DERIVATIVES, INTERMEDIATES USED IN THEIR PREPARATION, PREPARATION PROCESSES AND USE THEREOF | XINJIANG HUASHIDAN PHARMACEUTICAL RES CO LTD (CN) | 2011-07-27 | — | — | EP | claimed |
| US-20090227619-A1 | Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2009-09-10 | — | — | US | claimed |
| US-8772311-B2 | Harmine derivatives, intermediates used in their preparations, preparation processes and use thereof | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2014-07-08 | — | — | US | disclosed |
| US-8772311-B2 | Harmine derivatives, intermediates used in their preparations, preparation processes and use thereof | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2014-07-08 | — | — | US | disclosed |
| US-8772311-B2 | Harmine derivatives, intermediates used in their preparations, preparation processes and use thereof | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2014-07-08 | — | — | US | disclosed |
| EP-1634881-B1 | HARMINE DERIVATIVES, INTERMEDIATES USED IN THEIR PREPARATION, PREPARATION PROCESSES AND USE THEREOF | XINJIANG HUASHIDAN PHARMACEUTICAL RES CO LTD (CN) | 2011-07-27 | — | — | EP | disclosed |
| US-20090227619-A1 | Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2009-09-10 | — | — | US | disclosed |
| US-20090227619-A1 | Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2009-09-10 | — | — | US | disclosed |
| EP-1634881-A1 | HARMINE DERIVATIVES, INTERMEDIATES USED IN THEIR PREPARATION, PREPARATION PROCESSES AND USE THEREOF | Xinjiang Huashidan Pharmaceutical Research Co., Ltd. (CN) | 2006-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227619-A1 | Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo | TPH1, HTR1F, TPH2 | GABRP 2314/4885GABRD 3912/4885GABRA1 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.